UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Systemic juvenile idiopathic arthritis: Course, prognosis, and complications

Author
Yukiko Kimura, MD
Section Editor
Marisa Klein-Gitelman, MD, MPH
Deputy Editor
Elizabeth TePas, MD, MS

INTRODUCTION

Systemic juvenile idiopathic arthritis (formerly called Still's disease or systemic-onset juvenile rheumatoid arthritis [JRA]) is a subset of juvenile idiopathic arthritis (JIA). Adult-onset Still's disease (AOSD) is probably the same or similar disease when it begins in patients ≥16 years of age. Systemic JIA is classified as a subset of JIA, but the pathophysiology is most consistent with an autoinflammatory disorder. (See "Classification of juvenile arthritis", section on 'Systemic arthritis'.)

Children with systemic JIA require close supervision and careful monitoring. Systemic complications, including infections, macrophage activation syndrome (MAS), pericarditis, pulmonary hypertension, interstitial lung disease, and other forms of internal organ involvement, are more common in this subtype of JIA than in any other and are associated with increased mortality [1-3].

The clinical course, prognosis, and complications of systemic JIA are discussed in this review. The clinical manifestations, diagnosis, and treatment of systemic JIA are discussed separately, as are oligoarticular and polyarticular JIA. (See "Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis" and "Systemic juvenile idiopathic arthritis: Treatment" and "Classification of juvenile arthritis" and "Oligoarticular juvenile idiopathic arthritis" and "Polyarticular juvenile idiopathic arthritis: Clinical manifestations, diagnosis, and complications".)

COURSE

The course of systemic JIA is highly variable, which has prompted many observers to suspect that systemic JIA is not a single entity. The typical child with systemic JIA experiences a several-month period of spiking fevers and rash, with varying degrees of arthralgia and arthritis. This is often followed by a relative quiescence of the systemic manifestations. However, there are some children who have persistently active systemic disease, which is associated with worse outcomes [2,4]. (See 'Prognosis' below.)

Generally speaking, there are three disease-course patterns: monophasic, polycyclic, and persistent [4-6]. The actual proportions of systemic JIA patients who follow these disease course patterns are unclear since all studies looking at disease course were single-center studies and the definitions of remission and inactive disease were variable.

           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Nov 03 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Cassidy JT, Petty RE. Juvenile rheumatoid arthritis. In: Textbook of Pediatric Rheumatology, 4th ed, Cassidy JT, Petty RE (Eds), WB Saunders Company, Philadelphia 2001. p.218.
  2. Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013; 65:745.
  3. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 2014; 66:1405.
  4. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006; 54:1595.
  5. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000; 27:491.
  6. Fantini F, Gerloni V, Gattinara M, et al. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003; 30:579.
  7. Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46:2392.
  8. Schneider R, Lang BA, Reilly BJ, et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr 1992; 120:200.
  9. Spiegel LR, Schneider R, Lang BA, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000; 43:2402.
  10. Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015; 74:1854.
  11. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63:545.
  12. Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014; 66:1034.
  13. Oen K, Malleson PN, Cabral DA, et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29:1989.
  14. Svantesson H, Akesson A, Eberhardt K, Elborgh R. Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study. Scand J Rheumatol 1983; 12:139.
  15. Janow G, Schanberg LE, Setoguchi S, et al. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. J Rheumatol 2016; 43:1755.
  16. Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol 2014; 41:1171.
  17. Goel KM, Shanks RA. Follow-up study of 100 cases of juvenile rheumatoid arthritis. Ann Rheum Dis 1974; 33:25.
  18. Stoeber E. Prognosis in juvenile chronic arthritis. Follow-up of 433 chronic rheumatic children. Eur J Pediatr 1981; 135:225.
  19. Hashkes PJ, Wright BM, Lauer MS, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010; 62:599.
  20. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2385.
  21. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2396.
  22. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002; 41:1428.
  23. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85:421.
  24. Davì S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38:764.
  25. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012; 13:289.
  26. Kaufman KM, Linghu B, Szustakowski JD, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2014; 66:3486.
  27. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133.
  28. Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014; 66:3160.
  29. Davì S, Minoia F, Pistorio A, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66:2871.
  30. Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011; 17:23.
  31. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008; 4:615.
  32. Polito C, Strano CG, Olivieri AN, et al. Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol 1997; 26:99.
  33. Aggarwal B, Bhalla AK, Singh S. Longitudinal growth attainments of Indian boys with juvenile rheumatoid arthritis. Rheumatol Int 2011; 31:635.
  34. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 2009; 72 Suppl 1:20.
  35. Davies UM, Rooney M, Preece MA, et al. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J Rheumatol 1994; 21:153.
  36. Rooney M, Davies UM, Reeve J, et al. Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 2000; 27:1073.
  37. Bechtold S, Ripperger P, Mühlbayer D, et al. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 2001; 86:5737.
  38. Simon D, Lucidarme N, Prieur AM, et al. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol 2003; 30:2492.
  39. Bechtold S, Ripperger P, Bonfig W, et al. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol 2004; 31:1407.
  40. Bechtold S, Simon D. Growth abnormalities in children and adolescents with juvenile idiopathic arthritis. Rheumatol Int 2014; 34:1483.
  41. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43:1960.
  42. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:457.
  43. Compston JE. The therapeutic use of bisphosphonates. BMJ 1994; 309:711.
  44. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005; 90:494.